Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC Directories Mobile Apps Celebrity VCs VentureTrackr Archive About Us
 
VC-funded Company:


ImmusanT
One Kendall Square, Suite B2004
Cambridge, MA 02139
Phone: 617-299-8399
http://www.immusant.com/

ImmusanT is focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners.

Key Contact
NameTitleE-Mail
Leslie WilliamsCEO


Funding Events
DateAmountTypeInvestors
12/22/14$12,000,000Series B Vatera Healthcare Partners
11/14/17$40,000,000Series C ARCH Venture Partners
Vatera Healthcare Partners
 
Massinvestor/VC News Daily
617-620-4606


© 2017 Massinvestor, Inc.